25th Feb 2026 Plain language summary of sparsentan clinical trial findings in patients with focal segmental glomerulosclerosis
28th Aug 2025 Examining empagliflozin’s safety profile across four clinical trials: a plain language summary
23rd Sep 2024 Plain language summary: examining treatment outcomes in individuals with Fabry disease who began agalsidase beta therapy before age 30
20th Sep 2022 Plain language summary of a study looking at heart muscle thickness and kidney function in women with Fabry disease who received agalsidase beta treatment
